May 13, 2020 / 10:33 PM / 15 days ago

BRIEF-Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb 20717, PD-1 x CTLA-4 Bispecific Antibody, In Solid Tumors

May 13 (Reuters) - Xencor Inc:

* XENCOR REPORTS INITIAL DOSE-ESCALATION DATA FROM PHASE 1 STUDY OF XMAB®20717, PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN SOLID TUMORS

* XENCOR INC - XMAB20717 GENERALLY WELL-TOLERATED AND A CONFIRMED COMPLETE RESPONSE (CR) OBSERVED AT HIGHEST DOSE LEVEL TESTED

* XENCOR INC - ROBUST, DOSE-DEPENDENT IMMUNE ACTIVATION CONSISTENT WITH INHIBITION OF BOTH PD-1 AND CTLA-4 CHECKPOINTS FOR XAMB20717 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below